Vir Biotechnology, Inc. (VIR) Institutional Ownership

Ownership Summary

The institutional landscape for Vir Biotechnology, Inc. (NASDAQ:VIR) includes 211 filers as of the latest reporting cycle ending September 2025.

• The percentage of Vir Biotechnology owned by institutions changed from 77.8% in June 2025 to 77.0% in September 2025, marking a slight down trend.
• On a quarter-over-quarter basis, institutional holdings shifted by -0.18%, with a year-over-year an increase of 7.65% in the count of filers.
• A review of institutional activity for Vir Biotechnology shows 82 of 211 filers increasing their positions, while 86 reduced their stake, and 43 remained unchanged.
• Collectively, institutional investors decreased their stake in Vir Biotechnology to 106.91Mn shares as of September 2025, a change that is down by 189.83K shares quarter on quarter and up 18.41Mn shares year over year.
• As of September 30, 2025, SB INVESTMENT ADVISERS (UK) LTD held Vir Biotechnology's largest shareholding position with over 16.68Mn shares, representing 12.01% of total outstanding shares.
• Among the most significant buyers of Vir Biotechnology during September 2025 were MORGAN STANLEY (1.06Mn), MILLENNIUM MANAGEMENT LLC (787.21K), Aberdeen Group plc (519.37K), TWO SIGMA INVESTMENTS, LP (279.69K), PANAGORA ASSET MANAGEMENT INC (263.09K).
• Leading sellers of Vir Biotechnology stock in September 2025 included CITADEL ADVISORS LLC (818.19K), Ikarian Capital, LLC (474.69K), VANGUARD GROUP INC (427.69K), SCHRODER INVESTMENT MANAGEMENT GROUP (384.14K), PRUDENTIAL FINANCIAL INC (358.12K).
• The top 10 institutional holders of Vir Biotechnology for the quarter ending September 2025 included SB INVESTMENT ADVISERS (UK) LTD (16.68Mn), BlackRock, Inc. (15.97Mn), ARCH Venture Management, LLC (12.92Mn), VANGUARD GROUP INC (12.80Mn), STATE STREET CORP (5.24Mn), FMR LLC (3.64Mn), DIMENSIONAL FUND ADVISORS LP (2.98Mn), MORGAN STANLEY (2.69Mn), ORBIMED ADVISORS LLC (2.38Mn), GEODE CAPITAL MANAGEMENT, LLC (2.25Mn).